Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy;Antivitamines K et pharmacogénétique : vers une meilleure compréhension de la variabilité individuelle de l'effet dose-réponse

Pathologie Biologie

Volumn 55, Issue 6, 2007, Pages 295-298

  Siguret, V ^a,b  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; FLUINDIONE; MINISINTROM; PHENPROCOUMON; UNCLASSIFIED DRUG; WARFARIN; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE; VITAMIN K GROUP;

ALLELE; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENE; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; VENOUS THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1 GENE; DRUG ANTAGONISM; GENETICS; METABOLISM;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; HUMANS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS); VITAMIN K;

EID: 34447530280     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2007.04.001     Document Type: Article

References (27)

1. Stafford D.W. The vitamin K cycle. J. Thromb. Haemost. 3 (2005) 1873-1878
2. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.J., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004) 537-541
3. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
4. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 204S-233S
5. Kirchheiner J., and Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77 (2005) 1-16
6. Penning-van Beest F.J., van Meegen E., Rosendaal F.R., and Stricker B.H. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb. Haemost 86 (2001) 569-574
7. Visser L.E., Penning-van Beest F.J., Kasbergen A.A., De Smet P.A., Vulto A.G., Hofman A., et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb. Haemost. 88 (2002) 705-710
8. Franco V., Polanczyk C.A., Clausell N., and Rohde L.E. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am. J. Med. 116 (2004) 651-656
9. Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
10. Margaglione M., Colaizzo D., D'Andrea G., Brancaccio V., Ciampa A., Grandone E., et al. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84 (2000) 775-778
11. Taube J., Halsall D., and Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96 (2000) 1816-1819
12. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
13. Kamali F., Khan T.I., King B.P., Frearson R., Kesteven P., Wood P., et al. Contribution of age and body size and CYP2C9 genotype to anticoagulant. Clin. Pharmacol. Ther. 75 (2004) 204-212
14. Siguret V., Gouin I., Golmard J.L., Geoffroy S., Andreux J.P., and Pautas E. Polymorphismes du cytochrome P450 2C9 (CYP2C9) et posologie à l'équilibre pour des patients âgés traités par warfarine. Rev. Med. Intern. 25 (2004) 271-274
15. Gage B.F., Eby C., Milligan P.E., Banet G.A., Duncan J.R., and McLeod H.L. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91 (2004) 87-94
16. Bodin L., Verstuyft C., Tregouet D.A., Robert A., Dubert L., Funck-Brentano C., et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106 (2005) 135-140
17. Visser L.E., van Vliet M., van Schaik R.H.N., Kasbergen A.A.H., De Smet P.A.G.M., Vulto A.G., et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14 (2004) 27-33
18. Visser L.E., van Schaik R.H., van Vliet M., Trienekens P.H., De Smet P.A., Vulto A.G., et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb. Haemost. 92 (2004) 61-66
19. Verstuyft C., Robert A., Morin S., Loriot M.A., Flahault A., Beaune P., et al. Genetic and environmental risk factors for oral anticoagulant overdose. Eur. J. Clin. Pharmacol. 58 (2003) 739-745
20. D'Andrea G., D'Ambrosio R.L., Di Perna P., Chetta M., Santacroce R., Brancaccio V., et al. A polymorphism in VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2005) 645-649
21. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352 (2005) 2285-2293
22. Veenstra D.L., You J.H.S., Rieder M.J., Farin F.M., Wilkerson H.W., Blough D.K., et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in Hong Kong Chinese patient population. Pharmacogenet. Genomics 15 (2005) 687-691
23. Reitsma P.H., van der Heijden J.F., Groot A.P., Rosendaal F.R., and Büller H.R.A. C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2 (2005) 310-312
24. Schalekamp T., Brasse B.P., Roijers J.F., Chahid Y., van Geest-Daalderop J.H., de Vries-Goldschmeding H., et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 80 (2006) 13-22
25. Sconce E.A., Khan T.I., Wynne H.A., Avery P., Monkhouse L., King B.P., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 (2005) 2329-2333
26. Aquilante C.L., Langaee T.Y., Lopez L.M., Yarandi H.N., Tromberg J.S., Mohuczy D., et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79 (2006) 291-302
27. Gage B.F. Pharmacogenetics-based coumarin therapy. Hematology (Am. Soc. Hematol. Educ. Program) (2006) 467-473